X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1325) 1325
Publication (110) 110
Magazine Article (3) 3
Book Review (2) 2
Dissertation (2) 2
Newspaper Article (2) 2
Book / eBook (1) 1
Book Chapter (1) 1
Conference Proceeding (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (802) 802
male (734) 734
animals (600) 600
index medicus (583) 583
female (563) 563
fluorenes - administration & dosage (486) 486
fluorenes - therapeutic use (402) 402
drug combinations (388) 388
malaria (342) 342
rats (325) 325
adult (276) 276
infectious diseases (269) 269
malaria, falciparum - drug therapy (266) 266
ethanolamines - administration & dosage (255) 255
antimalarials - therapeutic use (254) 254
ethanolamines - therapeutic use (253) 253
middle aged (252) 252
artemisinins - therapeutic use (251) 251
treatment outcome (250) 250
artemisinins - administration & dosage (249) 249
antimalarials - administration & dosage (248) 248
child, preschool (231) 231
fluorenes - pharmacology (229) 229
drug therapy, combination (222) 222
research (222) 222
tropical medicine (217) 217
infant (193) 193
child (190) 190
parasitology (190) 190
parasitic diseases (178) 178
drug therapy (175) 175
adolescent (165) 165
fluorenes - adverse effects (165) 165
time factors (160) 160
pharmacology & pharmacy (157) 157
children (156) 156
artemether-lumefantrine (144) 144
administration, oral (140) 140
malaria - drug therapy (138) 138
aged (133) 133
efficacy (133) 133
fluorenes - pharmacokinetics (133) 133
mice (133) 133
plasmodium falciparum (132) 132
hepatitis c, chronic - drug therapy (131) 131
health aspects (128) 128
antimalarials (127) 127
artemether (122) 122
benzimidazoles - administration & dosage (119) 119
antiviral agents - administration & dosage (117) 117
care and treatment (116) 116
young adult (115) 115
fluorenes - metabolism (112) 112
plasmodium falciparum - drug effects (111) 111
antimalarials - adverse effects (109) 109
infectious and parasitic diseases (105) 105
plasmodium-falciparum malaria (104) 104
analysis (103) 103
genotype (103) 103
antiviral agents - therapeutic use (102) 102
artemisinins - adverse effects (101) 101
arctic medicine. tropical medicine (98) 98
dose-response relationship, drug (97) 97
sofosbuvir (97) 97
ethanolamines - adverse effects (96) 96
fluorenes - toxicity (96) 96
liver - metabolism (95) 95
uridine monophosphate - analogs & derivatives (94) 94
benzimidazoles - therapeutic use (91) 91
artesunate (90) 90
drug resistance (90) 90
safety (89) 89
hepatitis c (88) 88
infections (88) 88
hepacivirus - genetics (87) 87
dosage and administration (86) 86
malaria, falciparum - parasitology (86) 86
parasites (83) 83
therapy (83) 83
hepatitis c virus (82) 82
lumefantrine (82) 82
pharmacokinetics (82) 82
drugs (80) 80
antimalarials - pharmacokinetics (78) 78
public health (77) 77
drug administration schedule (76) 76
ribavirin (74) 74
ethanolamines - pharmacokinetics (73) 73
ledipasvir (73) 73
artemisinin (72) 72
fluorenes (72) 72
chloroquine (71) 71
sulfadoxine-pyrimethamine (71) 71
abridged index medicus (69) 69
medicine (69) 69
resistance (69) 69
drug dosages (68) 68
liver - drug effects (67) 67
toxicology (67) 67
medicine, general & internal (65) 65
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1196) 1196
German (90) 90
Russian (19) 19
Danish (8) 8
French (7) 7
Czech (4) 4
Chinese (3) 3
Dutch (2) 2
Hungarian (1) 1
Italian (1) 1
Polish (1) 1
Spanish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Hepatology, ISSN 0168-8278, 2015, Volume 63, Issue 6, pp. 1511 - 1522
Summary Failure to respond to the approved combinations of multiple direct-acting antiviral agents is relatively low in hepatitis C virus treatment... 
Gastroenterology and Hepatology | Daclatasvir | Simeprevir | Treatment | Resistance-associated variants | Ledipasvir | Interferon | Hepatitis C virus | Sofosbuvir | Direct-acting antivirals | Resistanceassociated variants | CHRONIC HCV | CHRONIC HEPATITIS-C | REAL-WORLD | PEGYLATED INTERFERON | DOUBLE-BLIND | GENOTYPE 1 INFECTION | INTERFERON-ALPHA 2A | GASTROENTEROLOGY & HEPATOLOGY | TREATMENT-NAIVE PATIENTS | DACLATASVIR PLUS SOFOSBUVIR | Uridine Monophosphate - administration & dosage | Humans | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Imidazoles - administration & dosage | Carbamates - administration & dosage | Simeprevir - administration & dosage | Uracil - administration & dosage | Benzimidazoles - administration & dosage | Ribavirin - administration & dosage | Treatment Failure | Protease Inhibitors - administration & dosage | Fluorenes - administration & dosage | Drug Therapy, Combination | Hepacivirus - drug effects | Antiviral Agents - therapeutic use | Clinical Trials as Topic | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Interferons - administration & dosage | Drug Resistance, Viral - genetics | Anilides - administration & dosage | Sofosbuvir - administration & dosage | Uridine Monophosphate - analogs & derivatives | Macrocyclic Compounds - administration & dosage | Sulfonamides - administration & dosage | Uracil - analogs & derivatives | Development and progression | Protease inhibitors | Drug resistance | Hepatitis C | Proteases
Journal Article
Gastroenterology, ISSN 0016-5085, 2016, Volume 151, Issue 3, pp. 457 - 471.e5
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 06/2017, Volume 64, Issue 12, pp. 1711 - 1720
Background. Large cohorts are needed to assess human immunodeficiency virus (HIV)/hepatitis C virus (HCV) real-world treatment outcomes. We examined the... 
real-world | HCV | HIV | DAA | INFECTIOUS DISEASES | HIV/HCV | LEDIPASVIR-SOFOSBUVIR | CHRONIC HEPATITIS-C | MICROBIOLOGY | COINFECTED INDIVIDUALS | IMMUNOLOGY | INFECTION | COHORT | Uridine Monophosphate - administration & dosage | Anilides - therapeutic use | Hepatitis C - drug therapy | Coinfection - drug therapy | Veterans | Humans | Middle Aged | Fluorenes - therapeutic use | Hepacivirus - genetics | Male | Carbamates - administration & dosage | Practice Patterns, Physicians | Benzimidazoles - administration & dosage | Ribavirin - administration & dosage | Female | Fluorenes - administration & dosage | Hepatitis C - complications | Registries | Drug Therapy, Combination | Benzimidazoles - therapeutic use | Uridine Monophosphate - therapeutic use | Hepacivirus - drug effects | Sofosbuvir - therapeutic use | Administration, Oral | Antiviral Agents - therapeutic use | HIV Infections - virology | Ribavirin - therapeutic use | Genotype | Treatment Outcome | Antiviral Agents - administration & dosage | Coinfection - virology | Macrocyclic Compounds - therapeutic use | Anilides - administration & dosage | Sofosbuvir - administration & dosage | Uridine Monophosphate - analogs & derivatives | HIV Infections - complications | Hepatitis C - virology | HIV Infections - drug therapy | Aged | Macrocyclic Compounds - administration & dosage | Sustained Virologic Response | Carbamates - therapeutic use | Cohort Studies | Antiviral agents | Care and treatment | Dosage and administration | Hepatitis C | HIV infection
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2017, Volume 66, Issue 6, pp. 1138 - 1148
Graphical abstract 
Gastroenterology and Hepatology | Antiviral agents | Ombitasvir | Ritonavir | Ledipasvir | Real-world | Genotype 1 | Paritaprevir | Sustained virologic response | Hepatitis C, Chronic | Sofosbuvir | Dasabuvir | Randomized controlled trials | PLUS RIBAVIRIN | VIRUS-INFECTION | CHRONIC HEPATITIS-C | SUSTAINED VIROLOGICAL RESPONSE | ALL-CAUSE MORTALITY | Chronic | HEPATOCELLULAR-CARCINOMA | TREATMENT-EXPERIENCED PATIENTS | Hepatitis C | GASTROENTEROLOGY & HEPATOLOGY | Uridine Monophosphate - administration & dosage | Humans | Middle Aged | Hepatitis C, Chronic - physiopathology | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Carbamates - administration & dosage | Neoplasm Recurrence, Local - etiology | Liver Neoplasms - etiology | Young Adult | Uracil - administration & dosage | Benzimidazoles - administration & dosage | Ribavirin - administration & dosage | Aged, 80 and over | Adult | Female | Fluorenes - administration & dosage | Carcinoma, Hepatocellular - etiology | Retrospective Studies | Drug Therapy, Combination | Glomerular Filtration Rate | Ritonavir - administration & dosage | Antiviral Agents - therapeutic use | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Spain | Anilides - administration & dosage | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Aged | Macrocyclic Compounds - administration & dosage | Sustained Virologic Response | Sulfonamides - administration & dosage | Cohort Studies | Uracil - analogs & derivatives | Genetic aspects | Safety and security measures | Hepatitis C virus
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2015, Volume 15, Issue 6, pp. 645 - 653
Summary Background Compared with other countries, patients with chronic hepatitis C infection in Japan tend to be older, have more advanced liver disease, and... 
Infectious Disease | INFECTIOUS DISEASES | SIMEPREVIR | INFECTION | CHRONIC HCV | Uridine Monophosphate - administration & dosage | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Drug-Related Side Effects and Adverse Reactions - pathology | Young Adult | Benzimidazoles - administration & dosage | Time Factors | Ribavirin - administration & dosage | Aged, 80 and over | Adult | Female | Fluorenes - administration & dosage | Fluorenes - adverse effects | Uridine Monophosphate - adverse effects | Benzimidazoles - adverse effects | Hepacivirus - isolation & purification | Administration, Oral | Japan | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Drug-Related Side Effects and Adverse Reactions - epidemiology | Asian Continental Ancestry Group | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Aged | Hepacivirus - classification | Sofosbuvir | Care and treatment | Liver | Dosage and administration | Product development | Drug therapy, Combination | Hepatitis C virus | Hepatitis C | Health aspects | Ribavirin | Hepatitis | Genotype & phenotype | Liver cancer | Heart attacks | Liver diseases | Human immunodeficiency virus--HIV | Hepatology | Response rates | Interferon | Infections | Drug dosages | Patients
Journal Article
JAMA, ISSN 0098-7484, 03/2015, Volume 313, Issue 12, pp. 1232 - 1239
Journal Article
by Landier, Jordi and Parker, Daniel M and Thu, Aung Myint and Lwin, Khine Shwe War and Lwin, Khin Maung and Delmas, Gilles and Nosten, Suphak and Nosten, François H and Andolina, Chiara and Aguas, Ricardo and Ang, Saw Moe and Aung, Ei Phyo and Baw, Naw Baw and Be, Saw Aye and B'Let, Saw and Bluh, Hay and Bonnington, Craig A and Chaumeau, Victor and Chirakiratinant, Miasa and Cho, Win Cho and Christensen, Peter and Corbel, Vincent and Day, Nicholas PJ and Dah, Saw Hsa and Dhorda, Mehul and Dondorp, Arjen M and Gaudart, Jean and Gornsawun, Gornpan and Haohankhunnatham, Warat and Hla, Saw Kyaw and Hsel, Saw Nay and Htoo, Gay Nay and Htoo, Saw Nay and Imwong, Mallika and John, Saw and Kajeechiwa, Ladda and Kereecharoen, Lily and Kittiphanakun, Praphan and Kittitawee, Keerati and Konghahong, Kamonchanok and Khin, Saw Diamond and Kyaw, Saw Win and Ling, Clare and Ma, Naw K' Yin and Marie, Alexandra and Maung, Cynthia and Marta, Ed and Minh, Myo Chit and Miotto, Olivo and Moo, Paw Khu and Moo, Merry and Moo, Ku Ler and Na, Naw Na and Nay, Mar and Nyo, Slight Naw and Oh, Eh Kalu Shwe and Oo, Tun Pyit and Oo, Phu Thit and Paw, Eh Shee and Phumiya, Choochai and Phyo, Aung Pyae and Pilaseng, Kasiha and Proux, Stéphane and Rakthinthong, Santisuk and Ritwongsakul, Wannee and Salathibuphha, Kloloi and Santirad, Armon and Sawasdichai, Sunisa and von Seidlein, Lorenz and Shee, Paw Bway and Shee, Paw Wah and Tangseefa, Decha and Thwin, May Myo and Tun, Saw Win and Wanachaloemlep, Chode and White, Lisa J and White, Nicholas J and Wiladphaingern, Jacher and Win, Saw Nyunt and Yee, Nan Lin and Yuwapan, Daraporn and Malaria Elimination Task Force Grp and Malaria Elimination Task Force Group
The Lancet, ISSN 0140-6736, 05/2018, Volume 391, Issue 10133, pp. 1916 - 1926
Journal Article
Journal Article
Journal of Pharmacy and Pharmacology, ISSN 0022-3573, 11/2017, Volume 69, Issue 11, pp. 1437 - 1446
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 04/2015, Volume 79, Issue 4, pp. 636 - 649
Journal Article